Haixa (Tranexamic Acid)

Haixa is indicated for several clinical situations in which reduction of bleeding is desired.

• Heavy menstrual bleeding (menorrhagia)
• Hereditary angioedema associated with increased fibrinolysis
• Trauma‑related bleeding, including postoperative bleeding
• Dental surgery bleeding where local hemostasis is required
• Prevention of bleeding in patients undergoing certain surgical procedures

Side effects of Haixa vary in frequency and severity.

Common

• Nausea
• Vomiting
• Abdominal pain or discomfort
• Headache

Serious

• Thromboembolic events (e.g., deep‑vein thrombosis, pulmonary embolism)
• Allergic reactions, including rash or angioedema
• Visual disturbances such as blurred vision or retinal changes

Precautions for Haixa focus on patient risk factors and clinical monitoring.

• Assess for a history of thromboembolic disease before initiating therapy
• Avoid use in patients with active intravascular clotting or recent myocardial infarction
• Use caution in individuals with renal impairment; dose adjustment may be required
• Pregnancy and breastfeeding status should be evaluated, as safety data are limited
• Discontinue Haixa prior to major surgery or invasive dental procedures to reduce clot‑related complications
• Monitor for signs of hypersensitivity throughout treatment

Drug interactions with Haixa can influence clotting risk or bleeding control.

Avoid

• Combined hormonal contraceptives containing estrogen, which may increase thrombotic risk
• Other antifibrinolytic agents used concurrently
• Direct thrombin inhibitors (e.g., dabigatran) that could potentiate clot formation

Use with caution

• Anticoagulants such as warfarin or direct oral anticoagulants
• Antiplatelet medications including aspirin and clopidogrel
• Non‑steroidal anti‑inflammatory drugs (NSAIDs)
• Selective serotonin reuptake inhibitors (SSRIs) that affect platelet function
• Patients with severe renal or hepatic impairment